Europe’s leading cancer meeting kicks off in Munich next week (Oct.19-23) and while smaller than its US counterpart ASCO, the big pharma players – and indeed the smaller ones – are increasingly using the ESMO congress to present data from major studies.
This year's meeting will see meat being put on the bones of some trials where impressive topline results have already been revealed. Chief among those will be the JAVELIN Renal 101 study of a combination of Merck KGaA and Pfizer Inc